Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Indivior Pharmaceuticals Inc. (INDV) vs Regencell Bioscience Holdings Limited (RGC)

Indivior Pharmaceuticals Inc. and Regencell Bioscience Holdings Limited are both Drug Manufacturers Specialty & Generic companies. Indivior Pharmaceuticals Inc. is the larger, with a market value of $4.3B against $3.1B — 1.4× the size. Regencell Bioscience Holdings Limited has negative trailing earnings, so its P/E is not meaningful; Indivior Pharmaceuticals Inc. trades at 12.4×. Indivior Pharmaceuticals Inc. has the higher net margin (26.8% vs 0.00%) and the higher return on invested capital (460.5% vs 0.00%). Across the 12 metrics below, Indivior Pharmaceuticals Inc. leads on 7 and Regencell Bioscience Holdings Limited on 5.

Valuation

Metric INDV RGC Drug Manufacturers Specialty & Generic median
P/E 12.40 n/m 20.14
P/S 3.20 n/m 2.25
P/B n/m n/m 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA 10.43 0.19 12.29
EV/Sales 3.42 n/m 2.56
Earnings yield 8.07% (16.69%) (2.99%)
Free cash flow yield (2.65%) 0.00% 0.00%

Profitability

Metric INDV RGC Drug Manufacturers Specialty & Generic median
Gross margin 81.97% — 53.94%
Operating margin 31.56% — 0.00%
Net margin 26.75% 0.00% 0.00%
Free cash flow margin (8.34%) 0.00% 0.00%
Return on equity (153.12%) 0.00% (0.40%)
Return on assets 26.52% 0.00% (3.32%)
Return on invested capital 460.53% 0.00% 0.00%

Growth

Metric INDV RGC Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 13.47% — 10.01%
EPS growth (last fiscal year) 3,017.87% 17.24% —
Revenue growth, 5-year CAGR 13.88% — 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric INDV RGC Drug Manufacturers Specialty & Generic median
Debt to equity (2.34) 0.00 0.05
Current ratio 0.84 1.42 2.31
Net debt to EBITDA 0.44 1.33 0.85

Dividend

Metric INDV RGC Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio — 0.00 0.00

Size

Metric INDV RGC Drug Manufacturers Specialty & Generic median
Market cap 4.25b 3.06b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack